Helicobacter pylori antimicrobial resistance rates in the central region of Portugal

Clinical Microbiology and Infection

Volumn 20, Issue 11, 2014, Pages 1127-1133

  Almeida, N ^a   Romaozinho J M ^a,b   Donato, M M ^b   Luxo, C ^c   Cardoso, O ^c   Cipriano, M A ^a   Marinho, C ^a   Fernandes, A ^a   Calhau, C ^b   Sofia, C ^a,b  

^a CENTRO HOSPITALAR E UNIVERSITÁRIO DE COIMBRA   (Portugal)

^b UNIVERSITY OF COIMBRA   (Portugal)

^c UNIVERSITY OF COIMBRA   (Portugal)

Author keywords

Helicobacter pylori; Antibiotics; Multidrug resistant; Mutations 23S rRNA; Mutations gyrA; Primary resistance; Secondary resistance

Indexed keywords

AMOXICILLIN; ANTIBIOTIC AGENT; CLARITHROMYCIN; DNA TOPOISOMERASE (ATP HYDROLYSING) A; LEVOFLOXACIN; METRONIDAZOLE; RNA 23S; TETRACYCLINE; UREA C 13; ANTIINFECTIVE AGENT;

ACADEMIC ACHIEVEMENT; ADULT; AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM CULTURE; BREATH ANALYSIS; EPSILOMETER TEST; FEMALE; FIRST DEGREE RELATIVE; GENE MUTATION; HELICOBACTER PYLORI; HOST; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SEX DIFFERENCE; STOMACH BIOPSY; STOMACH CARCINOMA; VERY ELDERLY; YOUNG ADULT; ADOLESCENT; BIOPSY; DNA SEQUENCE; DRUG EFFECTS; GENOTYPE; HELICOBACTER INFECTIONS; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MIDDLE AGED; PHENOTYPE; PORTUGAL; PREVALENCE; STOMACH MUCOSA;

BACTERIA (MICROORGANISMS); HELICOBACTER PYLORI;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-INFECTIVE AGENTS; BIOPSY; DRUG RESISTANCE, BACTERIAL; FEMALE; GASTRIC MUCOSA; GENOTYPE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; PHENOTYPE; PORTUGAL; PREVALENCE; PROSPECTIVE STUDIES; SEQUENCE ANALYSIS, DNA; YOUNG ADULT;

EID: 84917684924     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/1469-0691.12701     Document Type: Article

References (30)

1. Malfertheiner P, Megraud F, O'Morain CA et al. Management of Helicobacter pylori infection-the Maastricht IV/Florence Consensus Report. Gut 2012; 61: 646-664.
2. Graham DY, Fischbach L. Helicobacter pylori treatment in the era of increasing antibiotic resistance. Gut 2010; 59: 1143-1153.
3. Megraud F, Lehours P. Helicobacter pylori detection and antimicrobial susceptibility testing. Clin Microbiol Rev 2007; 20: 280-322.
4. Agudo S, Perez-Perez G, Alarcon T, Lopez-Brea M. High prevalence of clarithromycin-resistant Helicobacter pylori strains and risk factors associated with resistance in Madrid, Spain. J Clin Microbiol 2010; 48: 3703-3707.
5. Megraud F, Coenen S, Versporten A et al. Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption. Gut 2013; 62: 34-42.
6. Heep M, Kist M, Strobel S, Beck D, Lehn N. Secondary resistance among 554 isolates of Helicobacter pylori after failure of therapy. Eur J Clin Microbiol Infect Dis 2000; 19: 538-541.
7. Glupczynski Y, Megraud F, Lopez-Brea M, Andersen LP. European multicentre survey of in vitro antimicrobial resistance in Helicobacter pylori. Eur J Clin Microbiol Infect Dis 2001; 20: 820-823.
8. Bastos J, Peleteiro B, Barros R et al. Sociodemographic determinants of prevalence and incidence of Helicobacter pylori infection in Portuguese adults. Helicobacter 2013; 18: 413-422.
9. Bastos J, Peleteiro B, Pinto H et al. Prevalence, incidence and risk factors for Helicobacter pylori infection in a cohort of Portuguese adolescents (EpiTeen). Dig Liver Dis 2013; 45: 290-295.
10. Oleastro M, Pelerito A, Nogueira P et al. Prevalence and incidence of Helicobacter pylori infection in a healthy pediatric population in the Lisbon area. Helicobacter 2011; 16: 363-372.
11. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer 2013; 49: 1374-1403.
12. Glupczynski Y, Broutet N, Cantagrel A et al. Comparison of the E test and agar dilution method for antimicrobial susceptibility testing of Helicobacter pylori. Eur J Clin Microbiol Infect Dis 2002; 21: 549-552.
13. Oleastro M, Menard A, Santos A et al. Real-time PCR assay for rapid and accurate detection of point mutations conferring resistance to clarithromycin in Helicobacter pylori. J Clin Microbiol 2003; 41: 397-402.
14. Gerrits MM, van Vliet AH, Kuipers EJ, Kusters JG. Helicobacter pylori and antimicrobial resistance: molecular mechanisms and clinical implications. Lancet Infect Dis 2006; 6: 699-709.
15. Institute CaLS, eds. Performance standards for antimicrobial susceptibility testing; Seventeenth Informational Supplement. Wayne, PA: Institute CaLS, 2007.
16. Glocker E, Kist M. Rapid detection of point mutations in the gyrA gene of Helicobacter pylori conferring resistance to ciprofloxacin by a fluorescence resonance energy transfer-based real-time PCR approach. J Clin Microbiol 2004; 42: 2241-2246.
17. Glocker E, Berning M, Gerrits MM, Kusters JG, Kist M. Real-time PCR screening for 16S rRNA mutations associated with resistance to tetracycline in Helicobacter pylori. Antimicrob Agents Chemother 2005; 49: 3166-3170.
18. Atherton JC, Cao P, Peek RM Jr, Tummuru MK, Blaser MJ, Cover TL. Mosaicism in vacuolating cytotoxin alleles of Helicobacter pylori. Association of specific vacA types with cytotoxin production and peptic ulceration. J Biol Chem 1995; 270: 17771-17777.
19. Santos A, Queiroz DM, Menard A et al. New pathogenicity marker found in the plasticity region of the Helicobacter pylori genome. J Clin Microbiol 2003; 41: 1651-1655.
20. Podzorski RP, Podzorski DS, Wuerth A, Tolia V. Analysis of the vacA, cagA, cagE, iceA, and babA2 genes in Helicobacter pylori from sixty-one pediatric patients from the Midwestern United States. Diagn Microbiol Infect Dis 2003; 46: 83-88.
21. Cabrita J, Oleastro M, Matos R et al. Features and trends in Helicobacter pylori antibiotic resistance in Lisbon area, Portugal (1990-1999). J Antimicrob Chemother 2000; 46: 1029-1031.
22. Lopes AI, Oleastro M, Palha A, Fernandes A, Monteiro L. Antibiotic-resistant Helicobacter pylori strains in Portuguese children. Pediatr Infect Dis J 2005; 24: 404-409.
23. Kim JM, Kim JS, Kim N, Kim SG, Jung HC, Song IS. Comparison of primary and secondary antimicrobial minimum inhibitory concentrations for Helicobacter pylori isolated from Korean patients. Int J Antimicrob Agents 2006; 28: 6-13.
24. Samra Z, Shmuely H, Niv Y et al. Resistance of Helicobacter pylori isolated in Israel to metronidazole, clarithromycin, tetracycline, amoxicillin and cefixime. J Antimicrob Chemother 2002; 49: 1023-1026.
25. Peitz U, Sulliga M, Wolle K et al. High rate of post-therapeutic resistance after failure of macrolide-nitroimidazole triple therapy to cure Helicobacter pylori infection: impact of two-second-line therapies in a randomized study. Aliment Pharmacol Ther 2002; 16: 315-324.
26. Branca G, Spanu T, Cammarota G et al. High levels of dual resistance to clarithromycin and metronidazole and in vitro activity of levofloxacin against Helicobacter pylori isolates from patients after failure of therapy. Int J Antimicrob Agents 2004; 24: 433-438.
27. Francesco VD, Zullo A, Hassan C, Giorgio F, Rosania R, Ierardi E. Mechanisms of Helicobacter pylori antibiotic resistance: an updated appraisal. World J Gastrointest Pathophysiol 2011; 2: 35-41.
28. Adriaenssens N, Coenen S, Versporten A et al. European Surveillance of Antimicrobial Consumption (ESAC): outpatient antibiotic use in Europe (1997-2009). J Antimicrob Chemother 2011; 66 (Suppl 6): vi3-vi12.
29. Rimbara E, Noguchi N, Tanabe M, Kawai T, Matsumoto Y, Sasatsu M. Susceptibilities to clarithromycin, amoxycillin and metronidazole of Helicobacter pylori isolates from the antrum and corpus in Tokyo, Japan, 1995-2001. Clin Microbiol Infect 2005; 11: 307-311.
30. Sugimoto M, Yamaoka Y. Virulence factor genotypes of Helicobacter pylori affect cure rates of eradication therapy. Arch Immunol Ther Exp (Warsz) 2009; 57: 45-56.